Bronchodilator responsiveness in patients with chronic heart failure

Heart and Lung: Journal of Acute and Critical Care

Volumn 42, Issue 3, 2013, Pages 208-214

  Minasian, Armine G ^a   van den Elshout, Frank J J ^a   Dekhuijzen, P N Richard ^b   Vos, Petra J E ^a   Willems, Frank F ^a   van den Bergh, Paul J P C ^a   Heijdra, Yvonne F ^b  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Airway obstruction; Bronchodilator responsiveness; Chronic heart failure; Ipratropium; Salbutamol

Indexed keywords

IPRATROPIUM BROMIDE; SALBUTAMOL;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPIROMETRY; SYSTOLIC DYSFUNCTION; THORAX RADIOGRAPHY;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; BRONCHI; BRONCHODILATOR AGENTS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 84877111956     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2012.11.007     Document Type: Article

References (32)

1. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail 2008, 14:695-702.
2. Gehlbach B.K., Geppert E. The pulmonary manifestations of left heart failure. Chest 2004, 125:669-682.
3. Mancini D.M. Pulmonary factors limiting exercise capacity in patients with heart failure. Prog Cardiovasc Dis 1995, 37:347-370.
4. Kindman L.A., Vagelos R.H., Willson K., Prikazky L., Fowler M. Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide. Am J Cardiol 1994, 73:258-262.
5. Ng T.M., Munger M.A., Lombardi W.L., et al. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol 2002, 40:140-145.
6. Rolla G., Bucca C., Brussino L., Gallo W., Malara D. Bronchodilating effect of ipratropium bromide in heart failure. Eur Respir J 1993, 6:1492-1495.
7. Uren N.G., Davies S.W., Jordan S.L., Lipkin D.P. Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure. Eur Heart J 1993, 14:744-750.
8. Khan K.A., Jalal S., Jan V.M., et al. Pulmonary function profile in chronic congestive heart failure and the effect of ipratropium bromide. Indian Heart J 2000, 52:297-300.
9. Kurzawa R., Baron T., Grodzicki T. Pulmonary function test abnormalities in the elderly with systolic heart failure. Kardiol Pol 2007, 65:875-880. discussion 881-882.
10. Witte K.K., Morice A., Cleland J.G., Clark A.L. The reversibility of increased airways resistance in chronic heart failure measured by impulse oscillometry. J Card Fail 2004, 10:149-154.
11. Harrington D., Chua T.P., Coats A.J. The effect of salbutamol on skeletal muscle in chronic heart failure. Int J Cardiol 2000, 73:257-265.
12. Moore D.P., Weston A., Hughes J.M., Oakley C.M., Cleland J.G. Bronchial hyperresponsiveness in heart failure. N Engl J Med 1993, 328:1424-1425.
13. Light R.W., George R.B. Serial pulmonary function in patients with acute heart failure. Arch Intern Med 1983, 143:429-433.
14. Iversen K.K., Kjaergaard J., Akkan D., et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 2008, 264:361-369.
15. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHBLI/WHO workshop report.; 2010. http://www.goldcopd.org.
16. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
17. Global Initiative for asthma. Global strategy for asthma management and prevention. NHBLI/WHO workshop report.; 2010. http://www.ginasthma.org.
18. O'Hanlon R., O'Shea P., Ledwidge M., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007, 13:50-55.
19. Borg G.A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14:377-381.
20. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993, 16:5-40.
21. Maak C.A., Tabas J.A., McClintock D.E. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure?. J Emerg Med 2011, 40:135-145.
22. Perez-Padilla R., Hallal P.C., Vazquez-Garcia J.C., et al. Impact of bronchodilator use on the prevalence of COPD in population-based samples. COPD 2007, 4:113-120.
23. Hanania N.A., King M.J., Braman S.S., et al. Asthma in the elderly: current understanding and future research needs-a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol 2011, 128:S4-S24.
24. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
25. Hawkins N.M., Petrie M.C., Macdonald M.R., et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol 2011, 57:2127-2138.
26. Hanania N.A., Sharafkhaneh A., Celli B., et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011, 12:6.
27. Mentz R.J., Fiuzat M., Kraft M., Lindenfeld J., O'Connor C.M. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?. J Card Fail 2012, 18:413-422.
28. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125:2309-2321.
29. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:1439-1450.
30. Singh S., Loke Y.K., Enright P.L., Furberg C.D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011, 342:d3215.
31. Salpeter S.R. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence. Drugs 2009, 69:2025-2033.
32. Michele T.M., Pinheiro S., Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010, 363:1097-1099.